Auto Owners Insurance Co Acquires 1,987,362 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Auto Owners Insurance Co lifted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 8,892.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,009,712 shares of the medical equipment provider’s stock after acquiring an additional 1,987,362 shares during the quarter. Auto Owners Insurance Co’s holdings in Zimmer Biomet were worth $180,713,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. DV Equities LLC purchased a new position in Zimmer Biomet during the 4th quarter valued at $25,000. Monetary Solutions Ltd purchased a new stake in Zimmer Biomet in the fourth quarter worth about $30,000. Gen Wealth Partners Inc purchased a new position in shares of Zimmer Biomet in the 4th quarter valued at approximately $31,000. Flagship Harbor Advisors LLC purchased a new position in shares of Zimmer Biomet in the 4th quarter valued at approximately $32,000. Finally, Grove Bank & Trust boosted its position in shares of Zimmer Biomet by 431.6% during the fourth quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 328 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

ZBH stock opened at $88.13 on Friday. The company has a market cap of $17.05 billion, a P/E ratio of 22.89, a price-to-earnings-growth ratio of 2.59 and a beta of 0.47. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $108.29. The stock’s fifty day moving average price is $87.24 and its 200-day moving average price is $90.13.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The business had revenue of $2.09 billion for the quarter, compared to analysts’ expectations of $2.07 billion. During the same period last year, the firm posted $1.81 earnings per share. The business’s revenue for the quarter was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.49 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ZBH. Barclays decreased their price objective on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a report on Wednesday, April 29th. Wall Street Zen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Robert W. Baird set a $92.00 price target on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Canaccord Genuity Group set a $83.00 price objective on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Finally, Wells Fargo & Company cut their price objective on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $102.70.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the transaction, the insider directly owned 27,251 shares in the company, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.28% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.